Last reviewed · How we verify
Eulexin
At a glance
| Generic name | Eulexin |
|---|---|
| Also known as | flutamide |
| Sponsor | Radiation Therapy Oncology Group |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- WARNINGS Hepatic Injury There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking Eulexin ® . Evidence of hepatic injury included elevated serum transaminase levels, jaundice, hepatic encephalopathy and death related to acute hepatic failure. The hepatic injury was reversible after discontinuation of therapy in some patients. Approximately half of the reported cases occurred within the initial 3 months of treatment with Eulexin ® . Serum tr
Common side effects
- Hot flashes
- Diarrhea
- Impotence
- Loss of libido
- Nausea
- Skin rash
- Gastrointestinal disorders
- Anemia
- Anorexia
- Edema
- Leukopenia
- Skin irritation/rash
Serious adverse events
- Hepatic necrosis
- Hepatic encephalopathy
- Cholestatic jaundice
- Methemoglobinemia
- Sulfhemoglobinemia
- Hemolytic anemia
- Macrocytic anemia
- Photosensitivity reactions (erythema, ulceration, bullous eruptions, epidermal necrolysis)
- Malignant breast neoplasms
- Hepatitis and jaundice
Key clinical trials
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (PHASE3)
- Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer (PHASE3)
- Contributions to Hypertension With Androgen Deprivation Therapy (PHASE4)
- Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer (PHASE2)
- Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery (PHASE2, PHASE3)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
- Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eulexin CI brief — competitive landscape report
- Eulexin updates RSS · CI watch RSS
- Radiation Therapy Oncology Group portfolio CI